Therapeutic Effects of miR-29b-Enriched Nanovesicles on Mitochondrial Injury and Neuroinflammatory Processes in Alzheimer’s Disease
Neurotoxicity Research · 2026-10 · 44 (5)
DOI: 10.1007/s12640-026-00823-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurotoxicity Research, online erschienen am 24.08.2026. Verfasst von Sinan Gönüllü und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Bursa City Hospital, Bursa, Turkey. Hauptthemen laut MEDLINE: MicroRNAs, Alzheimer Disease, Mitochondria, Neuroinflammatory Diseases. Die Arbeit nennt 91 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is defined by the accumulation of extracellular amyloid-β plaques and intracellular neurofibrillary tangles, which drive neuronal and synaptic impairment. In AD, the accumulation of protein aggregates leads to neuroinflammation, increased oxidative stress, and mitochondrial damage, resulting in neuronal loss and cognitive impairment. Emerging evidence highlights that microRNAs (miRNAs) modulate AD-related pathological pathways and may offer opportunities for therapeutic intervention. In this study, we investigated the therapeutic potential of microRNA-29b (miR-29b) delivered via small extracellular vesicles (sEVs) in an in vitro neuroblastoma model of AD. Four experimental groups were established using SH-SY5Y neuroblastoma cells: (1) untreated control cells, (2) Aβ-treated cells to model AD-like pathology, (3) cells treated with unloaded sEVs, and (4) cells treated with miR-29b-loaded sEVs (sEV-miR-29b). To evaluate treatment effects, we assessed markers of oxidative stress (ROS, LDH, SOD, MDA, GPX1), neuroinflammation (BDNF, ICAM1, TNF-α, NfL, MIF, VEGFA, MCP-1), mitochondrial dysfunction (Cytc, TFAM, PINK1, DNM1L), synaptic integrity (CPLX2, ROR1), and AD pathology (Amyloid-β, Total Tau, pTau181, pTau217). Our findings demonstrate that treatment with sEV-miR-29b attenuated Aβ-induced oxidative stress, reduced pro-inflammatory signaling, and improved mitochondrial homeostasis compared with Aβ-only and sEV-only groups. Moreover, sEV-miR-29b treatment partially restored synaptic protein expression and decreased pathological tau phosphorylation. These results indicate that miR-29b plays a regulatory role in neuroinflammation, oxidative stress, and mitochondrial function, suggesting that sEV-mediated delivery of miR-29b represents a promising therapeutic strategy for modulating AD-related neurodegenerative mechanisms. This study highlights the potential of miR-29b-loaded sEVs as a therapeutic approach for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Bursa City Hospital, Bursa, Turkey.
- Department of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Turkey.
- Savur Prof. Dr. Aziz Sancar District State Hospital, Mardin, Turkey.
- Department of Neurology, Private Buhara Hospital, Erzurum, Turkey.
- Department of Basic Sciences, Faculty of Fisheries, Atatürk University, Erzurum, Turkey.
- Department of Neurology, Eskisehir City Hospital, Eskişehir, Turkey.
Zitieren
APA
Gönüllü, S., Dalkılınç, E., Çelik, O., Çelik, H., Küçükler, S., Topal, A., Akay, R., Yıldız, M. O., Alım, B., & Özdemir, S. (2026). Therapeutic Effects of miR-29b-Enriched Nanovesicles on Mitochondrial Injury and Neuroinflammatory Processes in Alzheimer’s Disease. Neurotoxicity Research, 44(5). https://doi.org/10.1007/s12640-026-00823-0
Vancouver
Gönüllü S, Dalkılınç E, Çelik O, Çelik H, Küçükler S, Topal A, et al. Therapeutic Effects of miR-29b-Enriched Nanovesicles on Mitochondrial Injury and Neuroinflammatory Processes in Alzheimer’s Disease. Neurotoxicity Research. 2026;44(5). doi:10.1007/s12640-026-00823-0
BibTeX
@article{Gnll2026,
author = {Gönüllü, Sinan and Dalkılınç, Elif and Çelik, Oğuz and Çelik, Hamit and Küçükler, Sefa and Topal, Ahmet and Akay, Ramazan and Yıldız, Mustafa Onur and Alım, Bülent and Özdemir, Selçuk},
title = {Therapeutic Effects of miR-29b-Enriched Nanovesicles on Mitochondrial Injury and Neuroinflammatory Processes in Alzheimer’s Disease},
journal = {Neurotoxicity Research},
year = {2026},
volume = {44},
number = {5},
doi = {10.1007/s12640-026-00823-0}
}
EUVIMED